Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Visiting the Zinc8 Energy Storage Development and Production Facility

The Dawn of the Utility-Scale Battery Era Following the latest press-releases and positive media coverage on the Collaboration Agreement between Zinc8 Energy Solutions Inc. and the New York Power Authority (NYPA) to deploy a 100kW/1MWh energy storage system in New...
Stephan Bogner | February 10, 2020 |

Buzz on the Bullboards: Of interest rates and rebates

Inflation continues to surge out of control to the point where grocery rebates seem to offer little help to struggling Canadians. This holiday-shortened week, markets are adjusting to the U.S. Federal Reserve’s move to raise interest rates. Investors a...
Jonathon Brown | July 6, 2023 |

We Should Let the Banks Burn Down

Bob Moriarty of 321 Gold explains why he believes banks should be allowed to fail. In later 2008 during what is now referred to as the Great Financial Crisis, government and financial managers had an opportunity to reset a badly out of balance banking system....
Streetwise Reports | August 7, 2019 |

Buzz on the Bullboards: Which stocks are turning inertia into momentum?

Markets have stumbled this week, especially tech indices as rising bond yields in the U.S. have had their way with the sector, which is sensitive to higher interest rates. One of the big updates of late, Datametrex AI Ltd. (TSXV:DM) brought investors up to spe...
Jonathon Brown | March 30, 2023 |

Reliq Re-establishes Itself as Community Care Technology Leader ...

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes A shift in the industry leads to big new contracts and parabolic stock performance for this small cap. A sweeping new development in what federal...
Streetwise Reports | November 14, 2019 |

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned

The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. In an Aug. 20 research note, analyst Ed Arce reported that H.C. Wainwright & Co. raised its target price on Nabriva Therapeutics Plc (NBRV:NASDAQ) to $8 per sh...
Streetwise Reports | August 28, 2019 |

MGX Renewables becomes Zinc8 Energy Solutions

Corporate Name Change & Management Realignment Yesterday after market close, MGX Renewables Inc. announced to change its corporate name to Zinc8 Energy Solutions Inc. to better reflect its competitive edge in providing solutions to the entire energy sector, and ...
Stephan Bogner | September 20, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Chimerix Shares Rise 50% as FDA Gives 'Go Ahead' for Phase 2/3 ALI Study in COVID-19 Patients

Shares of Chimerix Inc. traded higher after the company reported it has received U.S. FDA clearance to initiate a Phase 2/3 Study of dociparstat sodium in acute lung injury for patients afflicted with severe COVID-19. Biopharmaceutical company Chimerix Inc....
Streetwise Reports | April 29, 2020 |

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial

Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results ...
Streetwise Reports | December 30, 2019 |
1 2